$IMAB News

Last published 1y ago

1y agoIMABI-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech PlatformGlobeNewswireNew corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwideStrategy centers on broadening access to global capital and innovation
1y agoIMABI-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025GlobeNewswireUpdated Phase 1 givastomig monotherapy data show an impressive 18% ORR in metastatic gastric cancer patients who had received at least two prior lines of therapy. Responses were observed over a dose range from 5 mg/kg
1y agoIMABI-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge BiosciencesGlobeNewswireNew business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients
1y agoIMABI-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics ConferenceGlobeNewswireThe AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held October 22-26 in Boston, Massachusetts ROCKVILLE, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the
1y agoGTBP IMAB ENGN ONCO+1Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment ParadigmsPR NewswireEquity InsiderNews Commentary – Major pharmaceutical companies presenting at the European Society for Medical Oncology Congress October 17-21[1] are...
1y agoIMABI-Mab Announces Acceleration of Givastomig Investment and Leadership AppointmentsGlobeNewswireExpands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in combination with immunochemotherapy, in Q1 2026, with additional Phase 1b cohorts to
1y agoIMABI-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development CommitteeGlobeNewswireDr. Robert Lenz, Ms. Xin Liu and Dr. Sean Cao appointed to the Board of DirectorsResearch and Development Committee established to accelerate innovation and long-term growthDr. Ken Takeshita appointed to the Scientific
1y agoIMABI-Mab to Participate in September Investor ConferencesGlobeNewswireROCKVILLE, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer,
1y agoIMABI-Mab Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswirePositive givastomig Phase 1b dose escalation data in combination with immunochemotherapy in patients with 1L gastric cancers presented at ESMO GI 2025 showing 83% ORR at doses selected for ongoing expansion studyTopline
1y agoIMABI-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric CancersGlobeNewswireEnrollment in the planned second dose expansion cohort completed ahead of expectationsTopline results expected in Q1 2026 Positive Phase 1b dose escalation data presented at ESMO GI on July 2nd ROCKVILLE, Md., Aug.
1y agoIMABI-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary SharesGlobeNewswireROCKVILLE, Md., Aug. 01, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer,
1y agoIMABI-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge HealthGlobeNewswireAcquisition provides I-Mab with upstream rights to CLDN18.2 parental antibody for use in bispecific and multi-specific applications Acquisition eliminates all royalty obligations and reduces future milestones for
1y agoIMABI-Mab to Present at the BTIG Virtual Biotechnology ConferenceGlobeNewswireROCKVILLE, Md., July 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer,
1y agoIMABI-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025GlobeNewswireData show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or CLDN18.2
1y agoIMABI-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer ResearchGlobeNewswireMonotherapy efficacy and safety profile provided backbone for clinical development strategy in 1L combination with nivolumab plus chemotherapy ROCKVILLE, MD, June 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB)
1y agoIMABI-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025GlobeNewswire71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile 83% ORR (10/12) in patients across doses selected for ongoing dose expansion study Responses observed in
1y agoIMABI-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025GlobeNewswireVirtual investor event planned for July 8th at 2:00pm EDT Event to follow presentation of new Phase 1b combination dose escalation data for givastomig (Claudin 18.2 x 4-1BB bispecific antibody) at ESMO GI on July 2,
1y agoIMABI-Mab Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireROCKVILLE, Md., June 12, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) ("I-Mab" or the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment
1y agoIMABI-Mab to Participate in the H.C. Wainwright "HCW@Home" SeriesGlobeNewswireROCKVILLE, Md., June 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer,
1y agoIMABI-Mab to Present at Jefferies Global Healthcare ConferenceGlobeNewswireROCKVILLE, Md., May 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer,
1y agoIMABI-Mab Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswirePrioritization of givastomig as I-Mab's lead program positions the Company for clinical progressNew givastomig combination data selected for mini-oral presentation at ESMO GI, being held July 2-5 in Barcelona,
1y agoIMABI-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025GlobeNewswireROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer,
1y agoIMABI-Mab Reports Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswireContinued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in the first
1y agoIMABI-Mab to Present at 24th Annual Needham Virtual Healthcare ConferenceGlobeNewswireROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB), a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced
1y agoIMABI-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementGlobeNewswireROCKVILLE, Md., March 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) ("I-Mab" or the "Company"), announced today that on March 19, 2025 it received a written notice (the "Notice") from the Listing Qualifications
1y agoIMABI-Mab Announces Accelerated Givastomig Phase 1b Study ProgressGlobeNewswireEnrollment completed ahead of schedule in the first dose expansion cohortMomentum continues with first patient dosed in the second expansion cohortTopline results from the 40-patient dose expansion study expected in 1H
1y agoIMABI-Mab to Participate in Leerink Partners Global Healthcare ConferenceGlobeNewswireROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of precision immune-oncology agents for the treatment of
1y agoIMABI-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceGlobeNewswireROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer,
1y agoIMABI-Mab Announces Open Market Purchases of Company American Depositary Shares by Board MemberPR NewswireI-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the...
1y agoIMABI-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical ProgramPR NewswireI-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the...
1y agoIMABI-Mab to Participate at the Piper Sandler Healthcare ConferencePR NewswireI-Mab (NASDAQ: IMAB, the "Company"), a U.S.-based global biotech company, exclusively focused on the development of highly differentiated...
1y agoIMABI-Mab Reports Third Quarter 2024 ResultsPR NewswireI-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated...
2y agoIMABI-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive OfficerPR NewswireI-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated...
2y agoIMABI-Mab to Release Q3 2024 Financial Results on November 14, 2024PR NewswireI-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated...
2y agoIMABI-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024PR NewswireI-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated...
2y agoIMABI-Mab to Participate at the Truist Securities BioPharma SymposiumPR NewswireI-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the...
2y agoIMABI-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024PR NewswireI-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated...
2y agoIMABI-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung CancerPR NewswireI-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated...
2y agoIMABI-MAB (IMAB) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoIMABI-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business UpdatesPR NewswireI-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated...
2y agoIMABI-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment ConferencePR NewswireI-Mab (NASDAQ: IMAB), a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated...
2y agoIMABI-Mab to Release 1H 2024 Financial Results on August 28, 2024PR NewswireI-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated...
2y agoIMABI-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)PR NewswireI-Mab (NASDAQ: IMAB) ("I-Mab", the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential...
2y agoIMABI-Mab Announces Leadership TransitionsPR NewswireI-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has ...
2y agoIMAB SNY AZNI-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical OfficerPR NewswireI-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of ...
2y agoIMAB BMYI-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal CancersPR NewswireI-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of ...
2y agoIMABI-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024GlobeNewswireEncouraging objective responses were observed in heavily pre-treated patients, including 1 complete response (CR) and 6 partial responses (PR), mainly in patients previously treated with checkpoint inhibitorsPhase 1
2y agoIMABI-Mab to Participate at the Jefferies Global Healthcare ConferencePR NewswireI-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly...
2y agoIMABI-MAB Filed 2023 Annual Report on Form 20-FPR NewswireI-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of ...
2y agoIMABI-Mab to Participate at the 23rd Annual Needham Virtual Healthcare ConferencePR NewswireI-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly...